Revolution Medicines had been looking to sell Warp Drive's genomic drug discovery platform and microbial genome database since acquiring them in 2018.
Caprion said that the acquisition helps it acquire expertise in the analysis of myeloid-derived suppressor cells and expand its geographic coverage.
Edmonton-based Delta Genomics Centre becomes Neogen's fifth animal genomics laboratory, joining ones in Australia, Brazil, Scotland, and the US.
The company plans to use the technology, originally developed by Good Start Genetics, to offer sample preparation solutions and data analysis for NGS.
The assets include significant genetic data related to women's diseases and degenerative disc disease, which Predictive will use to develop gene-based diagnostics.
Waters said the acquisition is part of a strategy to develop simpler, more streamlined mass spec workflows that will be accessible to non-expert users.
Locus said it will pair the EpiBiome platform with its own CRISPR-based synthetic biology system to develop products that can edit the microbiome.
The acquisition nets Vela a US manufacturing and R&D site, as well as Great Basin's multiplexing platform and six existing FDA-approved products.
CFDRC obtained iXG's high-throughput antimicrobial discovery platform, EMAD (extremophilic microbiome antimicrobial discovery).
Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.